MUC1 and familial pancreatic carcinoma: Moreover, anti-MUC1 vaccines have shown promising results in phase I/II trials but have failed to show survival benefits compared to standard therapy in phase III trials such as Tecemotide in patients with stage III non-small-cell lung cancer or PANVAC C/F in patients with stage IV pancreatic cancer [19, 20].